公开(公告)号：US20190314481A1

公开(公告)日：2019-10-17

申请号：US16397214

申请日：2019-04-29

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon OH ,  Sandra ZURAWSKI ,  Gerard ZURAWSKI

IPC: A61K39/12 ,  C07K14/005 ,  A61K39/395 ,  C07K16/28 ,  C12N7/00

Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.

公开(公告)号：US20190184008A1

公开(公告)日：2019-06-20

申请号：US16141157

申请日：2018-09-25

Applicant: INSERM (Institut National de la Santé et de la Recherche Mêdicale ,  Baylor Research Institute ,  Universite Paris Est Creteil Val De Marne ,  Assistance Publique Hopitaux de Paris

Inventor： Yves Levy ,  Gerard Zurawski ,  Sandra Zurawski ,  Anne-Laure Flamar

IPC: A61K39/21 ,  C07K16/28 ,  A61P31/18 ,  C07K14/005 ,  C12N7/00

CPC classification number: A61K39/21 ,  A61K2039/505 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/6056 ,  A61K2039/627 ,  A61P31/18 ,  C07K14/005 ,  C07K16/2878 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2319/02 ,  C07K2319/40 ,  C12N7/00 ,  C12N2740/16134 ,  C12N2740/16171

Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).

公开(公告)号：US20190177391A1

公开(公告)日：2019-06-13

申请号：US16089128

申请日：2017-03-29

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Shuyuan CHEN ,  Paul A. GRAYBURN

IPC: C07K14/575 ,  A61P9/04 ,  A61P9/06 ,  A61P9/10 ,  C12N15/85 ,  A61K48/00 ,  A61K41/00 ,  A61K47/69

Abstract: Embodiments of the disclosure concern methods and compositions for treatment of a cardiac-related medical condition. In particular embodiments, ANGPTL8 is provided to an individual in need thereof for the treatment or prevention of a cardiac-related medical condition. In certain cases, ANGPTL8 is provided to an individual with cardiomyopathy, such as Adriamycin-induced cardiomyopathy, using ultrasound-targeted microbubble destruction.

公开(公告)号：US10286058B2

公开(公告)日：2019-05-14

申请号：US15111357

申请日：2015-01-13

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon Oh ,  Sandra Zurawski ,  Gerard Zurawski

IPC: A61K39/12 ,  A61K39/395 ,  C07K14/025 ,  C07K16/28 ,  C07K14/005 ,  C12N7/00 ,  A61K39/00

Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV 16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.

公开(公告)号：US20190046085A1

公开(公告)日：2019-02-14

申请号：US15574110

申请日：2016-05-11

Applicant: Baylor Research Institute

Inventor： Yair M. Levy ,  Houston Holmes

IPC: A61B5/11 ,  A61B5/00 ,  G16H50/20

Abstract: A system for improving the treatment of a patient's disease. A patient is fitted with a wireless motion capture device. A computer system receives the captured motion data other patient metric information and compares same to stored data sets. The stored data sets may comprise other motion data and/or metric data from the patient being examined, or captured data from other patients. The stored data sets can also be tagged with, or otherwise associated with, one or more treatment protocols. A model can be formed with respect to the patient's captured motion and other metric information. A probable treatment of the diseases, effectiveness of the patient's treatment regimen, and progression of the disease itself can be ascertained from the comparison.

公开(公告)号：US10190174B2

公开(公告)日：2019-01-29

申请号：US15672778

申请日：2017-08-09

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Ajay Goel ,  Yuji Toiyama ,  C. Richard Boland ,  Yoshinaga Okugawa

IPC: C12Q1/68 ,  C12Q1/6886 ,  A61B1/31 ,  A61B10/00 ,  A61B10/04

Abstract: Embodiments provide methods and compositions related to detecting neoplasia in ulcerative colitis patients by detection and analysis of the methylation state of miR-1, -9, -124, miR-137 and/or miR-34b/c in samples from UC patients.

公开(公告)号：US10167339B2

公开(公告)日：2019-01-01

申请号：US15501526

申请日：2015-08-03

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Yong-Jun Liu ,  Sandra Zurawski ,  SangKon Oh ,  Shino Hanabuchi ,  Haruyuki Fujita ,  Hideki Ueno ,  Patrick Blanco ,  Hyemee Joo

IPC: A61K39/395 ,  A61K39/00 ,  C07K16/28

Abstract: Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-α and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell—(Tfh) responses that may contribute to the pathogenicity of autoimmune disease.

公开(公告)号：US10071070B2

公开(公告)日：2018-09-11

申请号：US15587236

申请日：2017-05-04

Applicant: Baylor Research Institute

Inventor： Charles R. Roe

IPC: A61K31/20 ,  A61K31/19 ,  A61K31/194 ,  A61K31/23

CPC classification number: A61K31/20 ,  A61K31/19 ,  A61K31/194 ,  A61K31/23

Abstract: A method of treating patients in need of treatment for a cardiac disorder has been found which comprises administering to the patient a seven carbon fatty acid compound or derivative thereof, wherein the compound or derivative thereof is able to readily enter the mitochondrion without special transport enzymes. A dietary formulation suitable for treatment of heart tissue in cardiac or surgical patients has been found which comprises a seven-carbon fatty acid chain, wherein the seven-carbon fatty acid chain is characterized by the ability to transverse the inner mitochondrial membrane by a transport mechanism which does not require carnitine palmitoyltransferase I, carnitine palmitoyltransferase II, or carnitine/acylcarnitine translocase and the ability to undergo mitochondrial β-oxidation, and wherein the compound is selected from the group consisting of n-heptanoic acid or a derivative thereof, a triglyceride comprising n-heptanoic acid or a derivative thereof, and triheptanoin or a derivative thereof.

公开(公告)号：US20170349661A1

公开(公告)日：2017-12-07

申请号：US15501526

申请日：2015-08-03

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Yong-Jun LIU ,  Sandra ZURAWSKI ,  SangKon OH ,  Shino HANABUCHI ,  Haruyuki FUJITA ,  Hideki UENO ,  Patrick BLANCO ,  Hyemee JOO

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2875 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/76

Abstract: Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-α and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell- (Tfh) responses that may contribute to the pathogenicity of autoimmune disease.

公开(公告)号：US09750732B2

公开(公告)日：2017-09-05

申请号：US14729630

申请日：2015-06-03

Applicant: Baylor Research Institute

Inventor： Raphael Schiffmann ,  Fanny Mochel ,  Lawrence Sweetman ,  Sabrina Forni

IPC: A61K31/445 ,  A61B10/00 ,  G01N30/88

CPC classification number: A61K31/445 ,  A61B10/0051 ,  A61B10/0058 ,  A61B10/007 ,  A61B2010/0061 ,  G01N2030/8831

Abstract: The present invention describes a method for determination of urinary globotriaosylceramide (Gb3) levels in non-Fabry disease cardiac patients. Determination of Gb3 levels provides a screening method for determining cardiac risk and may offer an alternative therapeutic option for cardiac disease management or cardiac disease risk mitigation by lowering Gb3 levels by the use of pharmacological chaperones or other agents.